PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.43%
Positive net income growth while Biotechnology median is negative at -0.05%. Peter Lynch would view it as a strong advantage vs. struggling peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.55%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
69.28%
Working capital of 69.28% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
-92.45%
Other WC usage shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
109.32%
Growth of 109.32% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
22.94%
CFO growth of 22.94% while Biotechnology median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.52%
Debt repayment yoy declines while Biotechnology median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
1850.82%
Issuance growth of 1850.82% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.